CN115348962A - 作为GABAAα5受体调节剂的萘啶及吡啶并[3,4-c]哒嗪衍生物 - Google Patents

作为GABAAα5受体调节剂的萘啶及吡啶并[3,4-c]哒嗪衍生物 Download PDF

Info

Publication number
CN115348962A
CN115348962A CN202180023958.0A CN202180023958A CN115348962A CN 115348962 A CN115348962 A CN 115348962A CN 202180023958 A CN202180023958 A CN 202180023958A CN 115348962 A CN115348962 A CN 115348962A
Authority
CN
China
Prior art keywords
methyl
methoxy
methylpyridin
tetrahydro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023958.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·斯扎博
A·波托尔
I·瓦格
G·I·图罗斯
O·埃利拉斯
G·L·卡普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CN115348962A publication Critical patent/CN115348962A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180023958.0A 2020-03-26 2021-03-25 作为GABAAα5受体调节剂的萘啶及吡啶并[3,4-c]哒嗪衍生物 Pending CN115348962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2000113 2020-03-26
HUP2000113 2020-03-26
PCT/IB2021/052486 WO2021191838A1 (en) 2020-03-26 2021-03-25 NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
CN115348962A true CN115348962A (zh) 2022-11-15

Family

ID=89666363

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023958.0A Pending CN115348962A (zh) 2020-03-26 2021-03-25 作为GABAAα5受体调节剂的萘啶及吡啶并[3,4-c]哒嗪衍生物

Country Status (22)

Country Link
US (1) US20240067637A1 (https=)
EP (1) EP4126859A1 (https=)
JP (1) JP7805946B2 (https=)
KR (1) KR20220160061A (https=)
CN (1) CN115348962A (https=)
AR (1) AR121666A1 (https=)
AU (1) AU2021244926A1 (https=)
BR (1) BR112022019128A2 (https=)
CA (1) CA3171441A1 (https=)
CL (1) CL2022002568A1 (https=)
CO (1) CO2022014877A2 (https=)
CU (1) CU24714B1 (https=)
EC (1) ECSP22082367A (https=)
GE (2) GEP20257761B (https=)
IL (1) IL296716A (https=)
JO (1) JOP20220219A1 (https=)
MX (1) MX2022011933A (https=)
PE (1) PE20221836A1 (https=)
PH (1) PH12022552340A1 (https=)
TW (1) TWI901650B (https=)
WO (1) WO2021191838A1 (https=)
ZA (1) ZA202211414B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231691B1 (hu) * 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924452A (zh) * 2012-11-16 2013-02-13 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
CN103221402A (zh) * 2010-11-09 2013-07-24 霍夫曼-拉罗奇有限公司 三唑衍生物及其用于神经障碍的用途
CN103429582A (zh) * 2011-03-04 2013-12-04 莱西肯医药有限公司 Mst1激酶抑制剂及其用法
US20160102088A1 (en) * 2014-10-10 2016-04-14 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
WO2018104419A1 (en) * 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam
WO2018117196A1 (ja) * 2016-12-20 2018-06-28 大日本住友製薬株式会社 がん幹細胞を標的とする医薬
WO2020016443A1 (en) * 2018-07-20 2020-01-23 Boehringer Ingelheim International Gmbh Difluoromethyl-phenyl triazoles as gaba receptor modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
WO2007042420A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
KR101103129B1 (ko) 2005-11-09 2012-01-04 에프. 호프만-라 로슈 아게 3-아릴-아이속사졸-4-카본일-벤조퓨란 유도체
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
CA2876778A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2018101897A (ru) * 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
JP2018525429A (ja) 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド S1p調節剤としての縮合複素環化合物
HRP20221098T1 (hr) 2016-03-18 2022-11-25 Uwm Research Foundation, Inc. Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
IL279266B2 (en) 2018-06-13 2024-03-01 Hoffmann La Roche New isoxazolyl ether derivatives as gaba a alpha5 pam
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221402A (zh) * 2010-11-09 2013-07-24 霍夫曼-拉罗奇有限公司 三唑衍生物及其用于神经障碍的用途
CN103429582A (zh) * 2011-03-04 2013-12-04 莱西肯医药有限公司 Mst1激酶抑制剂及其用法
CN102924452A (zh) * 2012-11-16 2013-02-13 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
US20160102088A1 (en) * 2014-10-10 2016-04-14 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
WO2018104419A1 (en) * 2016-12-08 2018-06-14 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam
WO2018117196A1 (ja) * 2016-12-20 2018-06-28 大日本住友製薬株式会社 がん幹細胞を標的とする医薬
WO2020016443A1 (en) * 2018-07-20 2020-01-23 Boehringer Ingelheim International Gmbh Difluoromethyl-phenyl triazoles as gaba receptor modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS: "RN 2094711-87-0", STN REGISTRY *
CAS: "RN 2331259-79-9", STN REGISTRY, 12 June 2019 (2019-06-12) *
CAS: "RN 2331259-96-0", STN REGISTRY *
CAS: "RN 2411227-75-1", STN REGISTRY, 5 March 2020 (2020-03-05) *

Also Published As

Publication number Publication date
KR20220160061A (ko) 2022-12-05
ECSP22082367A (es) 2022-11-30
JP7805946B2 (ja) 2026-01-26
CU24714B1 (es) 2024-07-10
GEP20257761B (en) 2025-04-10
CA3171441A1 (en) 2021-09-30
PE20221836A1 (es) 2022-11-29
GEAP202416066A (en) 2024-12-10
US20240067637A1 (en) 2024-02-29
JP2023520647A (ja) 2023-05-18
TW202202495A (zh) 2022-01-16
PH12022552340A1 (en) 2023-11-29
JOP20220219A1 (ar) 2022-09-13
AR121666A1 (es) 2022-06-29
EP4126859A1 (en) 2023-02-08
CO2022014877A2 (es) 2022-10-31
TWI901650B (zh) 2025-10-21
BR112022019128A2 (pt) 2022-11-08
IL296716A (en) 2022-11-01
ZA202211414B (en) 2023-06-28
MX2022011933A (es) 2022-10-20
WO2021191838A1 (en) 2021-09-30
CU20220058A7 (es) 2023-05-11
CL2022002568A1 (es) 2023-03-24
AU2021244926A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
US20120135977A1 (en) Ether benzotriazole derivatives
WO2009070583A1 (en) Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
JP2003516989A (ja) Gaba受容体リガンドとしてのピラゾロ−ピリジン誘導体
EP3856342B1 (en) Bicyclic derivatives as gabaa a5 receptor modulators
JP5995841B2 (ja) 3,4−ジヒドロピロロ[1,2−a]ピラジン−2,8(1H)−ジカルボキサミド誘導体、その調製、およびその治療的使用
EP4126858B1 (en) Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
CN115348962A (zh) 作为GABAAα5受体调节剂的萘啶及吡啶并[3,4-c]哒嗪衍生物
CN118284606A (zh) 作为GABAA α5受体调节剂的双环胺衍生物
EA049237B1 (ru) ПРОИЗВОДНЫЕ НАФТИРИДИНА И ПИРИДО[3,4-c]ПИРИДАЗИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 5 РЕЦЕПТОРОВ GABAA
EA052124B1 (ru) БИЦИКЛИЧЕСКИЕ АМИНОПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ α5 РЕЦЕПТОРОВ GABAA
EA045543B1 (ru) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ α5 РЕЦЕПТОРОВ GABAA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination